## SYSTEMATIC REVIEW

# Which dietary patterns fend off nonalcoholic fatty liver disease? A systematic review of observational and interventional studies

Farnush Bakhshimoghaddam<sup>1,2</sup>, Daniel Baez<sup>3</sup>, Neda Dolatkhah<sup>4</sup>, Mahdi Sheikh<sup>5</sup>, Hossein Poustchi<sup>6</sup>, Azita Hekmatdoost<sup>7</sup>, Stanford Dawsey<sup>8</sup>, Farin Kamangar<sup>9,10</sup>, Christian Abnet<sup>8</sup>, Reza Malekzadeh<sup>9</sup>, Arash Etemadi<sup>8</sup> and Maryam Hashemian<sup>3,11\*</sup>

### Abstract

**Background** The global burden of non-alcoholic fatty liver disease (NAFLD) has significantly risen over the past decade. Dietary intake strongly influences its development and should be a component of any prevention and treatment plan strategy. Dietary pattern analysis enables the investigation of the overall diet and permits the consideration of interactions and cumulative effects of dietary components. The current study aimed to systematically review observational studies and intervention trials to determine the associations between various dietary patterns and NAFLD.

**Methods** The protocol was written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Embase, and the Cochrane Library. We included studies that reported a priori dietary pattern (i.e., diet quality scores) or *a posteriori* method, which identified existing eating patterns (i.e., principal component analysis) in adult participants. Two investigators conducted independent screening, extraction, and quality assessment using the Newcastle–Ottawa or Jadad scale. A third reviewer resolved conflicts.

**Results** We identified 27 relevant observational and 16 interventional studies from 16 countries. A Mediterranean or DASH diet might prevent and improve NAFLD, whereas dietary patterns such as Western dietary patterns characterized by high consumption of sweets and animal foods such as red meat and fast food are positively associated with NAFLD. A low-carbohydrate diet effectively prevents and treats NAFLD; however, we need more research on the effects of a low-fat diet and the type of fats.

**Conclusion** Healthy dietary patterns, mainly plant-based or adjusted macronutrient distributions, such as the adoption of a low-carbohydrate diet, are linked to a reduced risk of NAFLD and could halt its progression. We proposed recommendations for future studies to fill the gap in knowledge regarding the management of NAFLD via dietary modifications.

\*Correspondence: Maryam Hashemian maryam.hashemian2@nih.gov

Full list of author information is available at the end of the article



This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.



**Open Access** 

**Keywords** Dietary patterns, Hepatic steatosis, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Mediterranean diet, DASH, MAFLD

#### Introduction

Nonalcoholic fatty liver disease (NAFLD) is defined as a hepatic triglyceride content of more than 5% in the absence of significant alcohol consumption or any secondary causes for hepatic steatosis [1]. NAFLD encompasses a broad spectrum of liver dysfunctions, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis that may progress to hepatocellular carcinoma [2]. As NAFLD is linked to an increased risk for metabolic disease conditions, the prevention and management of NAFLD is one of the major public health challenges [1].

There is no specific treatment for NAFLD. However, lifestyle interventions, including physical activity, weight reduction, and dietary modification, are recommended as the primary options for the therapeutic management of NAFLD [3]. Since single nutrients or food groups are not consumed alone, exploring overall diet as a dietary pattern has been suggested to provide a more comprehensive view of the relationship between diet and chronic diseases, especially as components of these patterns may interact antagonistically or synergistically [4].

Despite considerable research, dietary strategies for the nutritional management of NAFLD are still an open issue. The optimal distribution of macronutrients to improve NAFLD is unclear. Recent studies reported that improving adherence to healthy dietary patterns, including the Mediterranean diet (MD) and Dietary Approaches to Stop Hypertension diet (DASH), which are characterized by an abundance of fruits, vegetables, and whole grains, may have an inverse association with hepatic steatosis [5]. Two systematic reviews of observational studies suggested that an unhealthy dietary pattern (a high intake of high-fat dairy products, red and processed meats, refined grains, and sweets) is associated with an increased risk of NAFLD. Conversely, a healthy diet (high in whole grains, legumes, fruits, vegetables, poultry, and fish) was associated with a reduced risk for NAFLD [6, 7]. However, interventional studies provide better evidence of any effects. A systematic review of only three interventional studies evaluating fatty liver by biopsy, MRI, and MRS demonstrated that MD reduced hepatic fat content [8]. Therefore, in this systematic review, we reviewed all studies that diagnosed and evaluated fatty liver disease with common NAFLD assessment tools and included both observational and interventional studies in this review to systematically review all available evidence and to ascertain the associations between dietary patterns consumed, macronutrient distribution and NAFLD.

#### Methods

The protocol for our systematic review was written using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines [9]. The purpose of the study was to determine the relationship between dietary patterns and NAFLD, and the protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42022340506). We included randomized and nonrandomized interventions and observational studies that evaluated dietary patterns and NAFLD in adult participants.

#### Search strategy

A comprehensive search was conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials. The merger of MeSH and non-MESH terms were composed by experts in the field and included the following terms: ("diet" OR "food" OR "eating" OR "eat" OR "dietary" OR "feeding" OR "nutrition" OR "nutrient" OR "dietary score" OR "Diet Quality Index" OR "Food Score" OR "Diet Score" OR "MedDietScore" OR "Dietary Pattern Score" OR "healthy eating index" OR "diet quality" OR "dietary pattern" OR "diet pattern" OR "eating pattern" OR "food pattern" OR "eating habit" OR "dietary habit" OR "food habit" OR "dietary profile" OR "food profile" OR "diet profile" OR "eating profile" OR "dietary guideline" OR "dietary recommendation" OR "food intake pattern" OR "dietary intake pattern" OR "diet pattern" OR "eating style" OR "DASH" OR "dietary approaches to stop hypertension" OR "Diet, Mediterranean" OR "Mediterranean" OR "vegan" OR "vegetarian" OR "Diet, Vegetarian" OR "prudent diet" OR "Western diet" OR "southern diet" OR "omniheart" OR "Optimal Macronutrient Intake Trial to Prevent Heart Disease" OR "Okinawa" OR "Ethnic Groups" OR "plant based") and ("Non-alcoholic fatty liver disease" OR "Non alcoholic fatty liver disease" OR "NAFLD" OR "Non-alcoholic steatohepatitis" OR "Non alcoholic steatohepatitis" OR "NASH" OR "MAFLD" OR "Metabolic Fatty Liver Disease" OR "MASLD" OR "Metabolic Dysfunction-Associated Steatotic Liver Disease"). To prevent missing relevant studies, a manual search of reference lists cited was conducted to identify articles that may not have been included within the electronic databases searched.

#### **Eligibility criteria**

Studies with the following conditions were included in this systematic review: (a) cohort, case-control, crosssectional studies, and clinical trials; (b) performed on individuals over 18 years of age; (c) reported a priori dietary patterns (hypothesis-driven approach) or *a posteriori* dietary patterns (exploratory approach); and (d) diagnosed NAFLD using valid methods, including liver biopsy, imaging methods or validated scores that predict NAFLD using biomarkers. The studies were restricted to those published in English up until September 2021. Table 1 shows the inclusion and exclusion criteria in detail.

#### **Data extraction**

Two independent reviewers (FB and DB) screened the titles and abstracts of the relevant studies and conducted the study selection, while a chief investigator (MH) was also present to resolve any disagreements. The full texts of potentially eligible articles were reviewed to identify relevant studies for inclusion. Two dietary pattern approaches were used: a priori methods, using dietary indices to evaluate the adherence of participants to a priori defined dietary patterns, such as the MD or a posteriori methods, using factor analysis, cluster analysis, or reduced rank regression to aggregate the participants into groups such as the Western diet. The following data were recorded from each study: first author's name, year of publication, method of diagnosing NAFLD, study design and duration, study location, study characteristics/group, dietary assessment tool, dietary pattern approach (a posteriori or a priori), type of dietary pattern (MD, and other), corresponding odds ratio (OR), relative risk (RR), or hazard ratio (HR) with 95% CI, and P value. We extracted the OR, RR, or HR values with the most adjustment models.

These two investigators also independently assessed the quality of each study by utilizing the Newcastle-Ottawa scale [10] for cohort, case-control, and cross-sectional studies and utilizing the Jadad scale [11] for randomized controlled trials. The Newcastle-Ottawa scale assigns up to a maximum of nine points for the least risk of bias in three domains: (a) selection of study groups (four points); (b) comparability of groups (two points); and (c) determining exposure and outcomes (three points) for casecontrol and cohort studies, respectively [10]. The Jadad scale utilizes a 3-item scale covering the randomization method, the blinding method, and withdrawals/dropouts. The Jadad scores range from 0 to 5, with  $\geq$ 3 points indicating a high-quality study and  $\leq 2$  points indicating a low-quality study [11]. The chief investigator resolved any discrepancies in the scores given to each paper.

#### Results

#### **Description of studies**

After searching the databases, we identified 2608 references, which were reduced to 2050 after excluding deduplications. Of the 2050 references screened by title and abstract, 73 went forward for inclusion and exclusion by reading the full text. Most studies had a low or moderate risk of bias, except for two studies, which scored below two according to the Jedad score. These were not included in the analysis [12, 13]. Additionally, we excluded one study as it had been flagged with an expression of concern by the publishers [14]. The body of evidence included 43 articles, 27 of which were interventional studies [5, 15–40] and 16 of which were interventional trials [41–56] (Fig. 1).

Category	Inclusion criteria	Exclusion criteria
Study design	Cohort Studies	Animal Studies
	Case-control Studies	Cellular and Molecular Studies
	Cross-sectional Studies	Systematic reviews
	Randomized clinical trials	
Intervention/Exposure	Studies that examined consumption of and/or adherence to a dietary pattern,	Did not provide a description of
	dietary score, or dietary index (i.e., Mediterranean Diet, Healthy Eating Index)	the dietary pattern
		Examined consumption of a single
		macronutrient vs. patient outcome
Comparison	Individuals in highest category of dietary scores compared to those in lowest	NA
	category	
Outcomes	Nonalcoholic fatty liver disease	Alcoholic fatty liver disease
Language of publication	English	Language other than English
Study participants	Human participants	Non-human participants
	Male participants	
	Female participants	
Age of study participants	Adults (aged 18–64 y)	Children and adolescents (aged
J , , , ,	Older adults (aged 65 y or older)	2–17 y)
Health status of study	Studies that enrolled participants who were healthy and/or at risk for NAFLD	Studies that enrolled participants
participants	Studies that enrolled participants who were diagnosed with NAFLD	who were diagnosed with a dis-
		ease or injury not related to NAFLD
Date of publication	No limit to September 2021	NA

**Table 1** The inclusion and exclusion criteria for study selection



Fig. 1 PRISMA flowchart of the search results and the included studies



Fig. 2 Distribution of countries included in the systematic review

Most studies included both males and females in their interventions (between 10 and 60% females), and only two studies were limited to males [52, 55]. The studies were conducted in 16 different countries. A total of 19 studies originated from Europe [5, 16, 17, 23, 27–31, 41–44, 46, 49, 51–53, 55], 17 from Asia and the Middle East [18–22, 24–26, 34–40, 47, 50], and six from North America and Australia [15, 32, 33, 45, 54, 56] (Fig. 2).

Dietary variables were measured by using a variety of instruments. Most studies utilized validated FFQs [5,

16–18, 20–23, 25–35, 37–41, 46–50, 53, 55, 57], whereas the remaining studies used dietary recalls (n=1) [15], food records (n=5) [24, 36, 45, 51, 56], a combination of dietary assessment tools (n=1) [44], a modified Burke diet history interview (n=1) [54], and not specified (n=4) [19, 42, 43, 52].

NAFLD was assessed using liver biopsy [30, 44]; imaging methods, including ultrasound [15, 17, 19–24, 26–29, 34–39, 41–43, 48, 51, 52, 55, 56], transient elastography [16, 25, 30, 46], CT scan [32, 40], magnetic resonance imaging (MRI) ) [5, 47, 49, 57], magnetic resonance spectroscopy (MRS) [18, 45, 50, 54], and nuclear magnetic resonance (NMR) [53]; or scores predicting NAFLD severity, including the fatty liver index (FLI) or triglyceride-glucose (TyG) criteria [28, 29, 31], and NAFLD score [28, 29]. The FLI includes several criteria, such as body mass index (BMI), waist circumference, gamma-glutamyl transferase (GGT), and triglyceride levels. TyG includes triglycerides and fasting plasma glucose. The NAFLD score includes the presence of metabolic syndrome, type 2 diabetes, fasting concentrations of insulin, aspartate aminotransferase (AST), and the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio [28, 29].

The results of the studies were reported according to study design, observational (Table 2) or interventional studies (Table 3).

#### **Observational studies**

Table 2 shows the characteristics of observational studies investigating the association of dietary patterns with nonalcoholic fatty liver disease, with 15 studies using a priori dietary patterns as follows:

#### Mediterranean dietary scores (MDS)

Of the 11 studies that assessed adherence to the MDS [5, 16–18, 23, 28–33], six reported that the MDS was inversely associated with steatosis or fibrosis, including two cohort studies [31, 32], one case-control study [23], and three cross-sectional studies [5, 17, 28]. The cohort study in the US used CT scans in the second-and third-generation Framingham Heart Study cohorts [32], and the cohort study in Greece used the TyG index [31].

Some articles reported nonsignificant results for adherence to the MDS: The Multiethnic Cohort Study (MEC) in the US using linkage to 1999–2016 Medicare claims [33], the Rotterdam study in the Netherlands using transient elastography [16], and the Swiss CoLaus Study in Switzerland using the FLI and NAFLD score for NAFLD diagnosis [29].

#### Dietary approach to stop hypertension (DASH)

In the four studies that reported adherence to the DASH diet, the MEC study [33], and two cross-sectional studies using MRI and ultrasound for diagnosis [5, 38], a significant inverse association between adherence to the DASH diet and NAFLD was reported. A case-control study by Hekmatdoost et al. using a fibroscan [25] showed null results.

# Healthy eating index (HEI) and alternative healthy eating index (AHEI)

In the MEC study, adherence to HEIs was significantly associated, while adherence to AHEIs was not associated with a reduced risk of NAFLD [33]. In the Framingham

cohort study, adherence to the AHEI was associated with a 21% decrease in the incidence of fatty liver [32]. A case-control study in Iran using ultrasound for diagnosis revealed no association between adherence to HEIs and NAFLD [24].

#### Other priori dietary patterns

A few studies evaluated adherence to the WHO score [16], Dutch dietary guidelines [16], dietary diversity score [24], Diet Quality Index International [18], and a vegetarian diet [19] (Table 2).

As Table 2 shows, 12 studies used posteriori dietary patterns. All of the *a posteriori* dietary patterns were extracted from case-control or cross-sectional studies. Studies that used a Posteriori dietary method showed that unhealthy dietary patterns [40], such as Western dietary patterns [34, 35], high carbohydrate intake, snacks, and sweets [15, 26, 36, 37], animal foods [37, 39], fast food [21, 22, 27, 37], and high meat [22, 36], were positively associated with NAFLD, whereas adherence to healthy dietary patterns [15, 34], plant-based food patterns [15, 35, 39, 40], dietary patterns consisting of high amounts of vegetables, low-fat dairy [21, 36], legumes [36], and simple meal patterns [20] were associated with a reduced risk of NAFLD. Nonsignificant associations were reported between some a posteriori-driven dietary patterns and NAFLD [15, 20, 21, 26, 27, 37], such as a high-protein diet [20, 27]. The traditional dietary patterns (TDPs) were country-specific, and the associations with NAFLD were not consistent. Negative [21, 22], positive [15, 20, 39], and null associations [34, 37] were reported for various a posteriori dietary patterns.

The limited number of studies precludes the conduct of a meta-analysis.

#### Interventional studies

We report the results of interventional studies for two outcomes: changes in NAFLD severity indices and changes in the levels of various liver enzymes.

#### NAFLD severity indices

All 16 articles reported a significant improvement in hepatic fat accumulation or stiffness despite intervention with a variety of dietary indices used as follows:

**Mediterranean Diet (MD)** *MD vs. control:* All four studies showed that adherence to an MD is more effective than a habitual or healthy diet [42, 43, 48, 50].

**Low-fat diet (LFD)** Of five studies [47, 53–56] investigating the effect of low-fat diets on liver steatosis, three found a significant reduction in liver steatosis.

Iable Z Chi	aracteristics of o	deervational studies investigating the association of dietary pa			ratty liver disease			
Author, Year (Reference)	Study Design	Study Characteristics	Method of NAFLD diagnosis	Dietary assess- ment tool	Dietary pattern	Method of Analysis	Effect Estimate (95%Cl)	Qual- ity as- sess- ment
Priori Dietary F Park et al. 2020 [33]	atterns Nested case- control within the Cohort	n = 32,251 (2959 with NAFLD and 29,292 without) in the Multiethnic Cohort study	linkage to 1999–2016 Medicare	FFQ	aMDS AHEI HEI	OR Q5 vs. Q1	1.0 (0.88–1.15) 0.91 (0.8–1.03) 0.83 (0.73–0.94)	œ
Ma et al. 2018 [32]	Cohort	oz % iertiale) age 45–75 USA n = 1521 participants with liver fat measured at Framingham Heart Study median follow-up: 6 y	CT scan	C EFQ	DASH A MDS	or q4 vs. Q1	0.78 (0.69–0.89) Liver fat de- creased: 0.57 (0.27–0.86) Incident fattv liver	ω
		usa usa			Δ AHEI scores		decreased: 26% (95% Cl, 10-39%) Liver fat de- creased: 0.56 (0.29-0.84) Incident fatty liver	
Kouvari et al. 2021 [ <b>3</b> 1]	Nested case- control within the Cohort	n = 3042 (1263 with NAFLD) in the ATTICA study follow-up: 10 y (51% female) Mean arce************************************	TyG index	FFQ	MDS	OR T3 vs. T1	decreased: 21% (5-35%) 0.53 (0.29–0.95)	~
Alferink et al. 2020 [16]	Cohort	Greece n = 343 patients with NAFLD in the Rotterdam Study median follow-up: 4.4 y (56% female) age 69–73 Nothorload	Transient elastography	FFQ	MDS Dutch Dietary Guidelines (healthy) WHO-score	OR per 1-unit increase in pattern	0.84 (0.66–1.05) 0.89 (0.71–1.12) 0.73 (0.53–1.00)	Ν
Khalatbari- Soltani et al. 2020 [29]	Cohort	Netherial us n = 153 patients with NAFLD (FLI) in the Swiss CoLaus Study follow-up: 5.3 y (65.4% female) mean age: 55.8 ± 10.0 Switzerland	FLI criteria and NAFLD score	0 FF	MDS	RR Q5 vs. Q1	FLI: 0.85 (0.71–1.02) NAFLD score: 0.95 (0.83–1.09)	œ
Giraldi et al. 2020 [23]	Case-control	n = 815 (371 with NAFLD and 444 without) (37% female) mean age: case: 59 $\pm$ 16.0 and control: 45 $\pm$ 14.4 Italy	Ultrasound	FFQ	MDS	OR per 1-unit increase in pattern score	0.83 (0.71–0.98)	~

Table 2 (cc	intinued)							
Author, Year (Reference)	Study Design	Study Characteristics	Method of NAFLD diagnosis	Dietary assess- ment tool	Dietary pattern	Method of Analysis	Effect Estimate (95%Cl)	Qual- ity as- sess- ment
Watzinger et al. 2020 <b>[5]</b>	Cross-sectional	n = 136 patients with NAFLD (50.7% female) age 35–65 Germany	MRI	FFQ	MDS DASH score	OR Q1 vs. Q4	4.41 (1.28–15.15) 4.41 (1.44–13.48)	4
Baratta et al. 2017 [17]	Cross-sectional	n = 584 patients with NAFLD (38.2% female) mean age: 55.8 ± 10.0 Italy	Ultrasound	FFQ	MDS	OR per 1-unit increase in pattern score	0.090 (0.01–0.79)	Ś
Khalatbari- Soltani et al. 2019 [28]	Cross-sectional	n = 2305 patients in the Fenland cohort and 1001 patients in the CoLaus cohort study, England and Switzerland	Ultrasound, FLI criteria, and NAFLD score	FFQ	SQM	PR Q5 vs. Q1	FLI: 0.82 (0.78– 0.86) in Fenland Study FLI: 0.85 (0.80– 0.91) in CoLaus Study	Ś
Hekmat- doost et al. 2016 [25]	Case-control	<i>n</i> = 306 (102 with NAFLD and 204 without) (57% female) mean age: 54.42 lran	Fibroscan	FFQ	DASH	OR Q4 vs. Q1	0.92 (0.73–1.12)	~
Xiao et al. 2020 [38]	Cross-sectional	<i>n</i> = 3051 patients with NAFLD (68% female) age 40-75 China	Ultrasound	FFQ	DASH score	OR Q5 vs. Q1	0.77 (0.61 – 0.97)	Ś
Hashemi Kani et al. 2013 [24]	Case-control	<i>n</i> = 200 (100 with NAFLD and 100 without) (60% female) mean age: 37.9 Iran	Ultrasound	3-day dietary record	HEI Dietary diversity score Dietary energy density Mean adequacy ratio of nutrients	0R Q1 vs. Q4	1.88 (0.76–2.95) 1.76 (0.68–2.89) 0.53 (0.19–0.89) 2.03 (0.91–4.03)	Q

ž
Ψ
_
~
. <b>`</b>
÷
5
~
0
0
$\sim$
~
•••
<b>(1)</b>
<u> </u>
ō
σ
_

Author, Year	Study Design	Study	Method	Dietary	Dietary pattern	Method of	Effect Estimate	Qual-
(Kererence)		Lnaracteristics	or INAFLU diagnosis	assess- ment tool		Analysis	(17%66)	iry as- sess- ment
Salehi-sahla- badi et al. 2021 [34]	Case-control	n = 675 (225 with NAFLD and 450 without) (47% female) mean age: control: 37.88 ± 8.92 and case: 38.63 ± 8.71 Iran	Ultrasound	FFQ	WDP HDP TDP	OR T3 vs. T1	3.64 (2.52–5.32) 0.30 (0.13–0.68) 1.21 (0.57–2.57)	ω
Tutunchi et al. 2021 [36]	Case-control	n = 210 (105 with NAFLD and 105 without) (57.2% female) age 30–60 Iran	Ultrasound	3-day dietary record	VLFD (healthy) SHMS (unhealthy)	OR T3 vs. T1	0.33 (0.11–0.84) 3.17 (1.04–6.66)	ω
Xia et al. 2020 [37]	Case-control	<i>n</i> = 4086 (2043 with NAFLD and 2043 without) based on TCLSIHealth Cohort Study (42% female) China	Ultrasound	FFQ	Sweet pattern AFP TDP	OR Q4 vs. Q1	1.01 (0.84–1.22) 1.23 (1.03–1.48) 0.92 (0.77–1.10)	ω
Dehghan- seresht et al. 2020 [21]	Case-control	<i>n</i> = 244 (122 with NAFLD and 122 without) (56% female) age 19–70 Iran	Ultrasound	FFQ	FFP TDP Vegetables and Dairy Ordinary pattern	OR T3 vs. T1	0.72 (0.26–1.96) 3.58 (1.48–8.68) 0.23 (0.09–0.58) 3.74 (1.23–11.42)	7
Kalafati et al. 2019 [27]	Case-control	<i>n</i> = 351 (134 with NAFLD and 217 without) (57% female) mean age: 50.4 Greece	Ultrasound	FFQ	Unsaturated fatty acids Prudent High protein pattern FFP	OR Q4 vs. Q1	0.82 (0.36–1.85) 0.70 (0.30–1.62) 1.67 (0.71–3.93) 4.24 (1.58–11.32)	~
Fakhoury- Sayegh et al. 2017 [22]	Case-control	n = 222 (112 with NAFLD and 110 without) (55% female) the mean age for cases: 39.9±6.0 and for control: 38.8±13.2 Lebanese	Ultrasound	FFQ	High-meat fast food High fruit TDP	OR per 1-unit increase in pattern score	4,08 (1.35–12.28) 4,06 (1.32–12.10) 0.30 (0.10–0.85)	ω
Chung et al. 2019 [20]	Cross-sectional	n = 331 patients with NAFLD (35.9% female) mean age: 51.1 South Korea	Ultrasound	FFQ	TDP Western and high-carbohydrate Simple meal pattern	OR Q5 vs. Q1	1.85 (1.11–3.08) 1.58 (0.92–2.73) 0.59 (0.34–1.00)	ъ

$\overline{\mathbf{D}}$
ā
≝
_
-
·=
Ļ
5
~
.0
9
9
<u>с</u>
5
e 2
le 2 (0
<b>ble 2</b> (c
able 2 (c
able 2 (c
Table 2 (c

Qual- ity as-	sess- ment	4	4	4	4			4	4
Effect Estimate (95%Cl)		0.61 (0.35–1.07) 2.73 (1.21–6.15)	1.05 (0.73–1.52) 1.42 (1.02–1.92) 1.05 (0.71–1.53) 0.70 (0.50–0.98)	2.99 (1.08–8.22) 0.35 (0.13–0.93)	Males: 0.80 (0.58–1.10) Females: 0.60 (0.36–1.01)	Males: 1.31 (0.98–1.75) Females: 1.04 (0.67–1.61)	Males: 0.99 (0.73–1.33) Females: 2.19 (1.40–3.46)	0.83 (0.66–1.06) 1.25 (0.99–1.59) 0.77 (0.62–0.98) 0.91 (0.71–1.17)	0.90 (0.79–1.02) 0.79 (0.64–0.97)
Method of Analysis		OR Q4 vs. Q1	PRT3 vs. T1	OR T3 vs. T1	OR Q4 vs. Q1			PR Q4 vs. Q1	OR per 1-unit increase in pattern score
Dietary pattern		Healthy Unhealthy	TDP Regional snacks Energy-dense Healthy	WDP Prudent	Balanced dietary pattern	High protein/ cholesterol	High carbohydrate/sweet	TDP AFP Grains-Vegetable High-Salt	MDS Diet Quality Index-International
Dietary assess-	ment tool	FFQ	24-h Dietary recall	FFQ	FFQ			FFQ	FFQ
Method of NAFLD 	diagnosis	CT scan	Ultrasound	Ultrasound	Ultrasound			Ultrasound	MRS
Study Characteristics		n = 1500 patients with NAFLD (42% female) mean age: 34.9 Iran	n = 229 older adults with NAFLD (74.4% female) mean age: 68.7 $\pm$ 6.4 Brazil	n = 58 patients with NAFLD (43.1% female) mean age: 49.32±13.84 South Korea	<i>n</i> = 4206 patients with NAFLD (30% female) mean age: 42 China			<i>n</i> = 999 patients with NAFLD (47% female) age: 45–60 China	<i>n</i> = 797 patients with NAFLD (58% female) age: 19–72 China
Study Design		Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional			Cross-sectional	Cross-sectional
Author, Year (Reference)		Ghaemi et al. 2018 [40]	Adriano et al. 2017 [15]	Shim et al. 2017 [35]	Q Jia et al. 2015 [26]			Yang et al. 2015 [39]	Chan et al. 2015 [18]

Author, Year (Reference)	Study Design	Study Characteristics	Method of NAFLD diagnosis	Dietary assess- ment tool	Dietary pattern	Method of Analysis	Effect Estimate (95%Cl)	Qual- ity as- sess- ment
Choi et al. 2015 [19]	Cross-sectional	<i>n</i> = 615 patients with NAFLD (38.8% female) mean age: 48.3 South Korea	Ultrasound		Vegetarian	OR per 1-unit increase in pattern score	1.27 (0.99–1.64)	4
Kontogianni et al. 2014 [30]	Cross-sectional	n = 73 patients with NAFLD (31.5% female) mean age: $45.4 \pm 11.3$ Greece	Transient elastography and liver biopsies	FFQ	MDS	OR per 1-unit increase in pattern score	1.03 (0.93–1.15)	ى.
AFP: animal foc fatty liver inde: SHMS: sweet, h	ods pattern; AHEI: al x; HEI: healthy eatin ydrogenated fat, re	ternative healthy eating index; aMDS: alternate Mediterranean diet score: g index; HDP: healthy dietary pattern; MD: Mediterranean diet; MDS: Med 1 and processed meat, and soft drink; TDP: traditional dietary pattern; TCLS	DASH: dietary ap literranean diet s SIHealth: Tianjin (	proaches to si core; MRI: mai Chronic Low- <u>c</u>	top hypertension; FFP: fast food r gnetic resonance imaging; OR: or jrade Systemic Inflammation and	pattern; FFQ: foc dd ratio; PR: pre l Health; TyG: Tri <u>c</u>	d frequency question valence ratios; RR: ha: Jlycerides-glucose inc	naire; FLI: ard ratio; ex; VLFD:

**Fable 2** (continued)

vegetables, legumes, fruits, and low-fat dairy products; WDP: western dietary patterr

*MD vs. LFD* Two studies have investigated the effect of MD vs. LFD on liver steatosis. One study on 24 obese patients showed that an MD is more beneficial than a low-fat diet [55], and another study on 100 patients with high cardiovascular risk showed no significant difference between these two dietary patterns [53].

*MD* combined with low carbohydrate diets vs. *LFD* or control Other studies have reported the effect of low carbohydrate plus MD (MD/LC) or low glycemic index plus MD (LGIMD) or carbohydrate-restricted diet vs. *LFD* or control group (following a healthy dietary pattern) on NAFLD [41, 45–47, 49, 51, 54, 56]. In summary, following a low carbohydrate/low glycemic index diet is effective in reversing steatosis.

**DASH** Other dietary patterns, including DASH, have been investigated in a few studies. The only RCT evaluating the DASH diet was excluded as it had been flagged with an expression of concern by the publishers [14].

Low-Carbohydrate Diet While there is no scientific consensus on the exact level of carbohydrate intake that defines a low-carbohydrate diet [58], some studies have utilized it as an intervention. According to the Browning et al. [45] study, two weeks of a low-carbohydrate diet (8% carbohydrate, 33% protein, 59% fat) significantly improved hepatic fat in 18 patients with NAFLD.

**Liver enzymes** A total of 12 studies measured changes in alanine transaminase (ALT) [41–45, 48, 49, 52–56], five studies measured changes in aspartate transaminase (AST) [41, 45, 49, 52, 55], and nine studies measured changes in gamma-glutamyl transpeptidase (GGT) [41– 44, 48, 49, 54–56].

**MD** *MD or LGIMD vs. control.* In five studies that investigated the effect of MD or LGIMD vs. conventional diets on liver enzymes, no difference was found between the groups [41–43, 48, 49].

**LFD** Two studies showed that a low-fat diet may improve liver enzymes [54, 55], and three studies showed null results [41, 51, 55].

MD vs. LFD or LFD/High Carbohydrate Diet (LFD/HCD):

In nine studies investigating the effect of MD vs. LFD/ HCD on transaminase enzymes, no difference was observed between the two groups [44, 47, 53–56]. Only Ristic-medic et al. [55] and Biolato et al. [44] reported that AST and ALT significantly decreased in the MD and LFD groups, respectively (P=0.02 and 0.04, respectively).

Low Carbohydrate Diet (LCD) In a study by Browning et al. (20 g carbohydrate/day) [45], only AST decreased

Table 3 Ch	aracteristics of in	nterventional s	studies investigat	ing the asso	ociation of dietary patterns w	ith nonalcoh	iolic fatty liver disease <sup>1</sup>		
Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment	Study groups	Dietary pattern	Results P values (before/after)	P values between groups	Quality assessment
Mediterranear	Diet (MD)			001					
Vaskolka	MRS	RCT Parallel	n = 794  observ	FFO	PA and energy-restricted	UCH	A IHF%: -12 2%	Oreen-MD	ſ
Meir et al.	<u>)</u>	18 months	dyslipidemia	9	diets for all groups (1200–	MD	Δ IHF%: -19.6%	vs. MD	1
2021 [ <mark>50</mark> ]			patients with		1400 kcal/d for women and	Green-MD	∆ IHF%: -38.9%	(P=0.03)	
			NAFLD		1500–1800 kcal/d for men)	)		green-MD	
			(12% female)		1. HDG (standard nutritional			vs. HDG	
			mean age: 51		counseling)			(P < 0.001)	
			Israel		2. MD (28 g/day walnuts)				
					3. green-MD [28 g/day				
					walnuts + 3–4 cups/day green				
					lea + Tou gru <i>Wonna grooose</i> (Mankai strain)]				
Abenavoli	Ultrasound	RCT,	n = 50 over-	Not	Energy-restricted diets for all	MD	Δ FLI: -26±13.6*	A FLI:	5
et al.		Parallel	weight patients	specified	groups (1400–1600 kcal/d)		(P = 0.002)	P = 0.02	
2017 [ <b>42</b> ]		6 months	with NAFLD		with CHO 50–60%, proteins		Δ ALT: 3 ± 6.6*	ALT:	
			(40% female)		15-20%, 20-35% fat		(P = 0.49)	P > 0.05	
			age 40–60		1. MD		$\Delta$ AST: 1 ± 2.2*	Δ AST:	
			Italy		2. MD + antioxidant complex		(P = 0.10)	P > 0.05	
					supplement (silymarin 120 mg,		∆ GGT: 5 ± 5.3*	∆ GGT:	
					chlorogenic acid 7.5 mg,		(P = 0.02)	P > 0.05	
					protopine	Control	△ FLI: 2.0 ± 7.6*		
					0.04 mg, L-methionine	group	(P = 0.07)		
					150 mg, L-glutathione 10 mg)	-	△ ALT: 5.0±16.0*		
					3. Control group (habitual diet)		(P = 0.88)		
							Δ AST: 4.0 ± 17.4*		
							(P = 0.02)		
							∆ GGT: 8.0±9.3*		
							(P = 0.04)		

liver disease <sup>1</sup>
nonalcoholic fatty
patterns with
n of dietary
e associatior

(2024) 10:153

Table 3 (cor	ntinued)								
Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment tool	Study groups	Dietary pattern	Results P values (before/after)	P values between groups	Quality assessment
Abenavoli et al. 2015 [43]	Ultrasound	RCT, Parallel 6 months	n = 30 over- weight patients with NAFLD (30% female) age 45–60 Italy	specified	Energy-restricted diets for all groups (1400–1600 kcal/day) with CHO 50–60%, proteins 15–20%, 20–35% fat 1. MD 2. MD plus antioxidant complex supplement (silybin 94 mg, phosphatidylcholine 194 mg, vitamin E acetate 89.28 mg) 3. Control group (habitual diet)	MD Control group	$ \Delta FLI: -32 \pm 14.2 * \ (P=0.02) \\ \Delta ALT: -17 \pm 21 * \ (P=0.31) \\ \Delta AST: 1 \pm 3.1 * \\ (P=0.31) \\ \Delta AST: 1 \pm 3.1 * \\ (P=0.32) \\ \Delta GGT: 5 \pm 6.3 * \\ (P=0.3) \\ \Delta ALT: 11 \pm 17.75 * \\ (P=0.03) \\ \Delta AST: 4 \pm 21.93 * \\ (P=0.03) \\ \Delta GGT: 10.0 \pm 9.93 * \\ (P=0.047) \\ (P=0.047) \\ \end{array} $	$\Delta$ FLI: <i>P</i> = 0.009 $\Delta$ ALT: <i>P</i> > 0.05 $\Delta$ GGT: <i>P</i> > 0.05 <i>P</i> > 0.05	σ
Katsagoni et al. 2018 [48]	Ultrasound	RCT, Parallel 6 months	n = 63 over- weight/obese patients with NAFLD (32% female) mean age: 50 $\pm$ 11 Greece	FFQ	Energy-restricted diets for all groups (1500 kcal/d for women 1800 kcal/d for men) with 45% CHO, 20% protein and 35% lipids 1. MD 2. Control group (healthy diet lifestyle) 3. MLG (increasing PA and improving sleep habits)	MD Control group	Δ Liver stiffness: -0.4 ± 2.1 ( <i>P</i> <0.05) Δ NAFLD fibrosis score: -2.48 ± 1.5 ( <i>P</i> >0.05) Δ ALT: -1.7 ± 2.1 * ( <i>P</i> >0.05) Δ GGT: -25 ± 31.7* ( <i>P</i> >0.05) Δ NAFLD fibrosis score: -2.2 ± 1.1 ( <i>P</i> >0.05) Δ Liver stiffness: 0.2 ± 2.4 ( <i>P</i> >0.05) Δ ALT: 0 ± 18.3* ( <i>P</i> >0.05) Δ GGT: 9 ± 63.5* ( <i>P</i> >0.05)	$\Delta$ NAFLD fibrosis score: P > 0.05 $\Delta$ Liver stiffness: P < 0.001 $\Delta$ ALT: P > 0.05 $\Delta$ GGT: P > 0.05	ى ب
Mediterranean	Diet (MD) vs. Low	Fat Diet (LFD)							

Table 3 (cc	ontinued)								
Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment tool	Study groups	Dietary pattern	Results P values (before/after)	<i>P</i> values between groups	Quality assessment
Ristic-medic et al. 2020 [55]	Ultrasound	RCT, Parallel 3 months	n = 24 over- weight/mod- erately obese patients with NAFLD (0% female) age 27–42 Serbia	O H	Energy-restricted diets for both groups (600–800 kcal/d reduction) 1. MD (50% CHO, 15% protein, 35% fat) 2. LFD (60% CHO, 15% protein, 25% fat)	MD LFD	Δ FLI: -38.7 ±6.0 (P < 0.001) Δ HIS: -8.3 ± 3.0 (P < 0.001) Δ ALT: -38 ± 19.1 (P < 0.001) Δ AST: -12.5 ± 10.5 (P < 0.001) Δ GGT: -23.1 ± 27.9 (P < 0.001) Δ GGT: -23.1 ± 27.9 (P < 0.001) Δ ALT: -31.2 ± 9.5 (P < 0.001) Δ ALT: -31.2 ± 9.5 (P < 0.001) Δ AST: -10.5 ± 0.1 (P = 0.006) Δ GGT: -15.4 ± 6.5 (P < 0.001)	$\Delta$ FL! P=0.02 $\Delta$ HIS: $\Delta$ ALT: P=0.13 $\Delta$ AST: P=0.02 $\Delta$ GGT: P=0.22	Ś
Pintó et al. 2019 [53]	NMR	3 years	n = 100 NAFLD patients with high cardiovas- cular risk (37% female) mean age: 64±6 67=1	0 H	<ol> <li>MD + EVOO (60 mL of extra- virgin olive oil per day)</li> <li>MD + mixed nuts (15 g walnuts, 7.5 g hazelnuts, and 7.5 g almonds per day)</li> <li>LFD (recommended to reduce fat)</li> </ol>	MD + EVOO MD + nuts LFD	Δ Liver fat:1.2% [0-4.4] (P>0.05) Δ ALT: 192 [16.6–28.4] (P>0.05) Δ Liver fat: 2.7% [0.2–11.0] (P>0.05) Δ ALT: 26.0 [19.8–36.5] (P>0.05) Δ Liver fat: 4.1% [0.6–10.4] (P>0.05) Δ ALT: 22.8 [17.1–38.1] (P>0.05)	Δ Liver fat: <i>P</i> = 0.07 Δ ΑLΤ: <i>P</i> = 0.27	L.
Mediterranea Properzi et al. 2018 [54]	ın Diet (MD) combin MRS	ed with low ca RCT, Parallel 3 months	irbohydrate diets n = 48 patients with NAFLD (49% female) mean age: 51 ± 13.4 Australia	Daily self- assessed checklists	1. MD (40% CHO, 35–40% fat, 20% protein) 2. LFD (50% CHO, 30% fat, 20% protein)	MD	$ \Delta \text{ hepatic fat: -10.2 \pm 9.9} (P < 0.001) $ $ \Delta \text{ ALT: -8 \pm 31.2} (P = 0.049) $ $ \Delta \text{ GGT: -19 \pm 72.0} (P < 0.001) $ $ \Delta \text{ hepatic fat: -6.2 \pm 6.0} (P < 0.001) $ $ \Delta \text{ ALT: -12 \pm 40.3} (P = 0.004) $ $ \Delta \text{ GGT: -19 \pm 75.6} (P = 0.05) $	Δ he- patic fat: P=0.72 Δ ALT: P=0.36 Δ GGT: P=0.72	Ś
Biolato et al. 2019 [44]	Liver biopsy	CCT, crossover 12 months	n = 20 patients with NAFLD (10% female) median age 43 Italy	24-h Dietary Recall and FFQ	Energy-restricted diets for both groups (1400 kcal/d) 1. MD (40% CHO, 20% protein, 40% fat) 2. LFD (62% CHO, 20% protein, 18% fat)	MD	Δ ALT: -28.3 ± 25 (P=0.001) Δ AST: -6.4 ± 9.7 (P=0.01) Δ GGT: -12.8 ± 7.0 (P>0.05) Δ ALT: 2.1 ± 23.4 (P>0.05) Δ AST: 2.5 ± 6.9 (P>0.05) Δ GGT: -30.0 ± 81.0 (P>0.05)	1	m

Table 3 (co	ontinued)								
Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment tool	Study groups	Dietary pattern	Results P values (before/after)	P values between groups	Quality assessment
Gepner et al. 2019 [47]	MRI	RCT, Parallel 18 months	n=278 abdomi- nal obesity/ dyslipidemia patients with NAFLD (11% female) mean age: 48 Israel	Q	<ol> <li>MD/LC (&lt;40 g/day CHO with a gradual increase up to 70 g/day, an increased protein and fat intake + 28 g walnuts)</li> <li>LFD (30% fat with 10% saturated fat and 300 mg of cholesterol)</li> </ol>	MD/LC LFD	Δ Hepatic fat (%): -7.3 ± 9.2 Δ Hepatic fat (%): -5.8 ± 7.2	$\Delta$ Hepatic fat (%): P = 0.04	2
Ryan et al. 2013 [56]	biopsy-proven NAFLD/MRS	RCT, cross-over 18 weeks	N=12 patients with NAFLD (50% female) mean age: 55±14 Australia	Food records	1. MD (40% CHO, 20% protein, 40% fat) 2. LFD/HCD (50% CHO, 20% protein, 30% fat)	MD/LC	$\Delta$ IHL%: -5.6 ± 7.4 ( $P < 0.05$ ) $\Delta$ ALT: -4.0 ± 17 ( $P > 0.05$ ) $\Delta$ GGT: -4.0 ± 19.2 ( $P > 0.05$ )	Δ IHL%: P=0.01 Δ ALT: P>0.05 Δ GGT: P>0.05	S
						LFD/HCD	Δ IHL%: -1.2±2.6 (P > 0.05) Δ ALT: -4.0±19.8 (P > 0.05) Δ GGT: -3.0±17.4 (P > 0.05)		
Abbate et al. 2021 [41]	Ultrasound	RCT, Parallel 6 months	n = 128 patients with MetS and NAFLD (40%female) age 40–60 Spain	FFQ	Energy-restricted diets for all groups 1. LGIMD–high meal fre- quency (40–45% CHO (LGI), 25% protein, 30–35% fat, 7 meals a day) 2. LGIMD–PA (> 40–45% CHO (LGI), 20% proteins, 35–40% fat, 4–5 meals a day) 3. Conventional Diet (fol- lowed the U.S. Department of Anticulture recommendations	LGIMD- high meal frequency Conven- tional Diet	$ \Delta \text{ Mean liver fat (\%): -6.6 \pm 10.6 (P < 0.001) } \\ \Delta \text{ ALT: -3.2 \pm 16.2 (P < 0.01) } \\ \Delta \text{ AST: -14.5 \pm 34.5 } \\ (P > 0.05) \\ \Delta \text{ GGT: -11.9 \pm 71.7 (P > 0.05) } \\ \Delta \text{ GGT: -11.9 \pm 71.7 (P > 0.05) } \\ \Delta \text{ Mean liver fat (\%): -4.9 \pm 7.8 (P < 0.001) } \\ \Delta \text{ ALT: -4.4 \pm 8.6 (P < 0.001) } \\ \Delta \text{ AST: -11.4 \pm 17.2 (P < 0.01) } \\ \Delta \text{ GGT: -14.7 \pm 23.2 (P < 0.001) } \\ \Delta \text{ GGT: -14.7 \pm 23.2 (P < 0.001) } \\ \end{array} $	$\Delta$ Mean liver fat (%): P = 0.03 $\Delta$ ALT: P > 0.05 $\Delta$ AST: P > 0.05 $\Delta$ GGT: P > 0.05	ч
					with 45–65% CHO, 10–35% protein, 20–35% fat				

	(								
Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment tool	Study groups	Dietary pattern	Results P values (before/after)	<i>P</i> values between groups	Quality assessment
Franco et al. 2020 [46]	FibroScan	3 months	n = 144 patients with moder- ate or severe NAFLD (38% female) mean age: 49.9 $\pm$ 10 Italy	Q	<ol> <li>LGIMD (no more than 10% of total daily calories are derived from saturated fats and an LGI with high MUFA and ω<sub>3</sub>PUFA)</li> <li>Control Diet (based on Italy guidelines)</li> <li>Aerobic Activity Program</li> <li>LGIMD + Aerobic Activity Program</li> <li>LGIMD + Combined Activity Program</li> </ol>	LGIMD Control Diet	Δ NAFLD score: (-34.84, 95% CI -64.34; - 5.34) ( <i>P</i> = 0.02) Δ NAFLD score: (-24.46, 95% CI -56.07; 7.15) ( <i>P</i> = 0.13)	∆ NAFLD score: P=0.15	m
Misciagna et al. 2017 [51]	Ultrasound	RCT, Parallel 6 months	n = 98 moder- ate to severe NAFLD patients (26% female) age 30-79 Italy	Dietary record	1. LGIMD (50% CHO, 15–20% protein, 30% fat) 2. Control diet (healthy diet recommended by WHO)	LGIMD Control diet	Δ FLI: -23.5 ± 20.6 ( <i>P</i> < 0.05) Δ FLI: -9.6 ± 16.2 ( <i>P</i> < 0.05)	∆ FLI: P < 0.05	Ŋ
Marin- Alejandre et al [49] 2019	MRI	RCT, Parallel 6 months	n = 98 patients with NAFLD and overweight or obese (47% female) gge 40–80 Spain	С Ц	PA and energy-restricted diets for both groups (1200–1500 kcal/d) 1. FLiO (based on the MD prin- ciples with 40–45% CHO (LGI), 25% protein, 30–35% fat) 2. Control (followed by the American Heart Association with 50–55% CHO, 15% pro- tein, 30% fat)	FLiO (LGIMD) Control	$\Delta \text{Liver fat (%): -4.2 \pm 3.5 (P < 0.001)}$ $\Delta \text{Liver stiffness: -0.1 \pm 0.5}$ (P = 0.18) $\Delta \text{FL}: -29 \pm 14.6$ (P < 0.001) $\Delta \text{AST: -2 \pm 5.3 (P = 0.30)}$ $\Delta \text{ALT: -11.6 \pm 11.9 (P < 0.001)}$ $\Delta \text{ALT: -11.6 \pm 11.9 (P < 0.001)}$ $\Delta \text{GGT: -7.2 \pm 27.5 (P < 0.001)}$ $\Delta \text{GGT: -7.2 \pm 27.5 (P < 0.001)}$ $\Delta \text{Liver fat (%): -3.6 \pm 3.3 (P < 0.001)}$ $\Delta \text{Liver stiffness: 0.1 \pm 0.5 (P = 0.20)}$ $\Delta \text{Liver stiffness: 0.1 \pm 0.5 (P = 0.20)}$ $\Delta \text{ALT: -10.2 \pm 11.2 (P < 0.001)}$ $\Delta \text{ALT: -10.2 \pm 11.2 (P < 0.001)}$ $\Delta \text{GGT: -12.6 \pm 17.4 (P < 0.001)}$	$\Delta$ Liver fat (%): P=0.71 $\Delta$ Liver stiffness: P=0.12 $\Delta$ AST: P=0.12 $\Delta$ AST: P=0.12 $\Delta$ ALT: P=0.47 $\Delta$ GGT: P=0.69	Ω
Low Carbohyc	Jrate Diet								

Table 3 (continued)

Author, Year (Reference)	Method of NAFLD diagnosis	Study Design Duration	Study Characteristics	Dietary assess- ment tool	Study groups	Dietary pattern	Results P values (before/after)	<i>P</i> values between groups	Quality assessment
et al. 2011 [45]	MRS	RCT, Parallel 2 weeks	N = 18 patients with NAFLD (72.8% female) mean age: 45 ± 12 USA	Dietary record	<ol> <li>Carbohydrate-restricted diet (8% CHO, 33% protein, 59% fat)</li> <li>Calorie-restricted diet (1500 kcal for men and 1200 kcal for women with 50% CHO, 16% protein, 34% fat)</li> </ol>	Carbo- hydrate- restricted diet calorie- restricted diet	Δ Hepatic fat (%): -55±14 (P<0.001) Δ AST: -33±18 (P<0.05) Δ ALT: 18±47.6 (P>0.05) Δ ALT: 18±47.6 (P>0.05) Δ ALT: 4±30 (P<0.05) Δ ALT: 4±30 (P>0.05)	$\Delta$ Hepatic fat (%): P < 0.001 $\Delta$ AST: P = 0.30 $\Delta$ ALT: P = 0.80	m
Pe 'rez- Guisado et al. 2011 [52]	Ultrasound	Single arm 12 weeks	N = 14 obese patients with MS and NAFLD (0% female) mean age: 41.18 ± 2.28 Spain	Not specified	1. SKMD (unlimited energy diet with < 30 g/day CHO)	SKMD	∆ ALT: -34.8 ± 9.2 ( <i>P</i> < 0.001) ∆ AST: -18.4 ± 7.6 ( <i>P</i> < 0.001)	1	m
<sup>1</sup> Values are me ALT: alanine tra gamma-glutan	ans±SDs or [IQR] u ansaminase; AST: a: ኅyl transferase; HD0	nless otherwise i spartate transam G: healthy dietar	ndicated. *Medians± ninase; ALP: alkaline y guidelines; HFC: he	: SDs phosphatase epatic fat con	; BLS: bright liver score; CCT: contro ttent: HIS: hepatic steatosis index: IF	olled clinical tr HF: intrahepati	ial; EVOO: extra-virgin olive oil; FLI: fatty liver ind. c fat: LFD: low-fat diet: LF/HCD: low fat/hindh carb	ex; FLiO: fatty liv ohvdrate diet: LG	er in obesity; GGT: IMD: low alvcemic

spectroscopy; MUFA: monounsaturated fatty acids; NMR: nuclear magnetic resonance; PA: physical activity; PUFA: polyunsaturated fatty acids; RCT: randomized controlled trial; SKMD: Spanish ketogenic Mediterranean diet

in both the carbohydrate- and calorie-restricted groups (P<0.05). According to the Pe'rez-Guisado et al. [52] study, a 12-week Spanish Ketogenic Mediterranean Diet (SKMD) (<30 g carbohydrate/day) significantly improved ALT (P<0.001) and AST (P<0.001) levels in 14 obese men with NAFLD.

#### Sensitivity analyses

When we restricted our study to cohort studies to limit recall bias, two studies reported MD [29, 31], one study reported HEI and DASH [33], one study reported AHEI [32], and one study reported that WHO dietary patterns [16] are associated with a decreased risk of NAFLD. When we restricted our results to articles that used biopsy, MRI, or MRS as accurate methods for NAFLD diagnosis, we found that the MD, DASH, MD/LC, lowcarbohydrate diet, and LFD methods are all beneficial for managing NAFLD [5, 18, 30, 44, 45, 47, 49, 50, 54, 56].

Several studies have evaluated the effects of supplements [42, 43], sleep habits [48], and physical activity [41, 48] as a separate group of interventions. We have not included these results in the tables since the purpose of this study was to evaluate dietary patterns only, and there were few of these separate groups.

#### Discussion

Our study showed that most of the studies on dietary patterns and NAFLD evaluated the MD, and the evidence demonstrated that adhering to an MD is associated with a lower risk of NAFLD [5, 17, 23, 28, 31, 32]. Additionally, most interventional studies have shown the benefits of MD in improving intrahepatic lipids, which can ultimately improve NAFLD [41–44, 47–50, 54–56]. Additionally, the use of other healthy dietary patterns, such as DASH, or the manipulation of macronutrient distribution, such as a low-glycemia/low-carbohydrate diet, could be effective in reversing steatosis. Studies that used *a posteriori* diet showed that unhealthy dietary patterns, such as Western dietary patterns characterized by high consumption of sweets, red meat, and fast food, were positively associated with NAFLD.

#### MD

Concerning the prevention of chronic disorders, one of the most well-known dietary patterns in the literature is the MD [59]. However, there are various MD scoring systems, such as 9-point and 14-point scales which could potentially challenge the validity of our results. The MD is characterized by an abundance of plant foods, vegetables, fruits, legumes, whole grains, nuts, fish, extra virgin olive oil, and less consumption of dairy, poultry, and red and processed meat [60]. Moreover, MD improves NAFLD through its antioxidant and anti-inflammatory effects. The MD is rich in monounsaturated fatty acids (MUFAs), omega-3 polyunsaturated fatty acids (PUFAs), fibers, and polyphenols, which have been found to have a beneficial effect on glycemic and lipoprotein metabolism and therefore on NAFLD. MUFAs improve metabolic parameters such as glycemic disorders, lipid metabolism, and blood pressure, decreasing the risk of NAFLD [61]. Omega-3 PUFAs show beneficial effects via a reduction in the inflammatory response and oxidative stress and improvement of insulin sensitivity and therefore can decrease hepatic steatosis [62]. Furthermore, dietary fiber can reduce the risk of type 2 diabetes, dyslipidemia, and NAFLD by increasing the production of short-chain fatty acids and phenolic compounds, both of which act as antioxidants and modulate the gut microbiota [63]. Polyphenols, as an important component of an MD, are found in foods such as olive oil, nuts, and red wine (when consumed in moderation). Mitochondrial dysfunction is directly associated with chronic diseases, and polyphenols exert their beneficial effects by regulating genes and signaling pathways that influence inflammation, mitochondrial function, and oxidative stress [64].

#### DASH

The DASH diet pattern was associated with improved NAFLD parameters such as liver steatosis in observational studies [5, 25, 33, 38, 57]. However, its effectiveness in NAFLD management has rarely been investigated in interventional studies. Dietary patterns based on DASH emphasize the consumption of whole grains, legumes, seeds, nuts, vegetables, fruits, low-fat dairy products, fish, and chicken, with a reduction in red meat, fat, sweet, and sugary drink consumption [65]. Whole grains and nuts are important components of the DASH diet and contribute to the reduction of risk factors and disease severity of NAFLD due to the nutrients, fibers, and phytochemical composition [66, 67]. DASH diets also include fruits and vegetables with high natural antioxidants, which are beneficial for managing NAFLD [68]. The MD and DASH dietary patterns have most of their recommendations in common, but the MD does not include dairy, while the DASH contains low-fat dairy.

#### Other dietary patterns

Furthermore, other studies have shown an inverse association between NAFLD and other healthy dietary patterns. Various labels were assigned to different healthy dietary patterns, including MD, DASH, HEI, AHEI, and plantbased diets. However, all nutrient-dense diets, that provide a high amount of essential nutrients, were associated with a reduced risk of NAFLD [5, 16, 18, 19, 32, 33, 38, 57]. This consistency across nutrient-dense dietary patterns with different names has been reported in other studies with different outcomes [69–72].

According to studies that assessed dietary patterns using the *a posteriori* method, unhealthy dietary patterns, including the Western dietary pattern, and dietary patterns characterized by high consumption of sweets and animal foods such as red meat and fast food were positively associated with NAFLD [21, 22, 27, 36, 37]. The Western dietary pattern is often regarded as a diet containing a high amount of refined sugars and saturated fats that can affect metabolic pathways and increase intrahepatic triglycerides by stimulating adipose tissue lipolysis. Furthermore, excess energy from simple sugars leads to an increase in triglycerides in the liver through de novo lipogenesis [73]. Previous studies evaluating the association between animal foods and sweets as a food item and NAFLD showed similar findings [74, 75].

In contrast, adherence to a healthy diet rich in high amounts of fruit, vegetables, legumes, and low-fat dairy was associated with a reduced risk of NAFLD [21, 36]. These findings are similar to those of previous studies on NAFLD and specific food items, including whole grains [76], legumes [77], low-fat dairy [78], and vegetables [75]. However, we observed conflicting results for fruits. In the Fakhoury-Sayegh et al. [22] study, a dietary pattern characterized by more than 2-3 servings/d of fruits increased the odds of NAFLD, while Tutunchi et al. [36] reported that a healthy dietary pattern characterized by high consumption of fruit, vegetables, legumes, and low-fat dairy products was associated with a reduced risk for NAFLD. Furthermore, in healthy dietary patterns, approximately 2 servings/day of fruits are recommended. This discrepancy may be explained by the fact that fruits contain simple carbohydrates, such as fructose, which has been associated with NAFLD and metabolic syndrome components, including visceral adiposity, dyslipidemia, insulin resistance, and hypertension [79]. When exposed to high loads of fructose, enterocytes metabolize more fructose locally, leading to an increase in de novo lipogenesis. Excess fructose can contribute to the formation of triglycerides, which may enter circulation, raising the risk of developing NAFLD or other metabolic disorders [80]. The discrepancy observed may also stem from limitations inherent in certain methodologies used for dietary data collection.

#### Diet based on macronutrient distribution

The optimal distribution of macronutrients to improve NAFLD is unclear. However, the current review revealed that manipulating the macronutrient composition by restricting carbohydrate content [41, 45–47, 49, 51, 56] plays a key role in improving NAFLD. Nevertheless, there is still no scientific consensus on the specific level of carbohydrate intake that defines a low-carbohydrate diet [58]. A few studies have shown that a low-fat diet may improve NAFLD [47, 54, 55]. An LFD usually limits fat energy to less than 30% of total daily calories, while less than 20% is considered a very LFD [81]. However, we noticed that the authors defined the low-fat diet differently, from 18 to 30%, or even only advised

the participants to decrease fat intake [53]. This could be the reason for inconsistent results on the effect of LFD on NAFLD. More studies are needed to compare LFD with MD and LFD with LCD/LGI.

#### Strengths and limitations

Providing up-to-date information about NAFLD and different dietary patterns and manipulating macronutrient distribution using both observational and interventional studies is one of the main strengths of this systematic review. We used two popular methods to evaluate the risk of bias in the studies, and most studies had a low to moderate risk of bias. Moreover, it encompasses a variety of populations with different dietary patterns and various designs, providing a more reliable and generalized view of the topic from various perspectives. However, there are several limitations. The first limitation is that there is heterogeneity in studies regarding the duration of intervention and follow-up, characteristics of participants, the timing of data collection, and outcome criteria. Different methods have been used for NAFLD diagnosis, and even studies that used an accurate method for diagnosis, such as biopsy, did not repeat the accurate method for follow-up. Varying diagnostic criteria can result in misclassification bias. Studies that use imaging techniques (e.g., ultrasound, MRI) may have different sensitivity and specificity compared to studies using liver biopsy. This makes it difficult to directly compare results across studies and reduces the strength of any pooled estimates. Variations in dietary assessment tools like FFQs, 24-hour recalls, or dietary diaries with distinct advantages and limitations can introduce bias or variability in the results. Differentiating between the scoring systems of dietary patterns such as MD in the analysis was beyond the scope of this study. The transition from NAFLD to MAFLD toward the end of the study period limited the available studies on MAFLD, highlighting the need for future systematic reviews [82]. Moreover, publication bias should be considered in this systematic review. All published studies were analyzed, while unpublished studies were not considered. The dietary patterns extracted via exploratory methods may vary in different populations; for example, the Western dietary pattern in one population is not the same as that in another population. Since this review takes a comprehensive approach, the methodological heterogeneity of the dietary patterns covered allows for qualitative analysis.

#### **Recommendations for future studies**

The aforementioned limitations prompted us to develop reporting recommendations for future studies to fill the gap in knowledge regarding the management of NAFLD via dietary modifications:

More research in different countries is needed. There were no studies from Africa or South America.

- The effectiveness of the DASH diet for NAFLD management has rarely been investigated in interventional studies.
- All of the *a posteriori* dietary patterns were extracted from cross-sectional or case-control studies that are prone to recall bias. The use of cohort studies is recommended for more exploratory dietary patterns.
- More interventional research is needed to evaluate the optimal macronutrient proportions. More research on low-fat diets, especially on the percentage of fat as well as the type of fats, including MUFAs and PUFAs, is needed. More studies are needed to compare LFD with MD and LFD with LCD/LGI.
- More interventional studies on the effect of fruit consumption on NAFLD are needed.
- More high-quality research using accurate methods for the diagnosis of NAFLD in both diagnosis and follow-up is needed.
- Given the recent shift in terminology from NAFLD to MAFLD, future studies would benefit from utilizing the updated MAFLD criteria in literature searches and analysis.

#### Conclusions

Our results demonstrated that following a healthy dietary pattern such as the MD or DASH diet is an effective way to prevent and manage NAFLD. All other healthy dietary patterns characterized by high consumption of vegetables, whole grains, nuts and legumes, vegetable oils, and fish were associated with a lower risk of NAFLD, and unhealthy dietary patterns such as Western dietary patterns characterized by high consumption of sweets, red meat, and fast food were positively associated with NAFLD. A low-carbohydrate diet is effective at preventing and treating NAFLD; however, more research on a low-fat diet is needed.

#### Abbreviations

AHEI	Alternative healthy eating index
ALP	Alkaline phosphatase
ALT	Alanine transaminase
AST	Aspartate aminotransferase
BMI	Body mass index
DASH	Dietary approaches to stop hypertension
HEI	Healthy Eating Index
evoo	Extra virgin olive oil
FLI	Fatty liver index
LCD	Low-carbohydrate diet
lfd	Low-fat diet
LF/HCD	Low fat/high carbohydrate diet
lgimd	Low glycemic index Mediterranean diet
MD	Mediterranean diet
MD/LC	Mediterranean/low-carbohydrate
MRI	Magnetic resonance imaging
MRS	Magnetic resonance spectroscopy
MUFA	Mono-unsaturated fatty acid
NAFLD	Nonalcoholic fatty liver disease
NASH	Nonalcoholic steatohepatitis

WDP Western dietary patterns

#### Acknowledgements

The authors alone are responsible for the content and writing of the paper. We thank Nancy Terri, MLS, and NIH for providing the literature search strategy. We also thank Janis Winn, a Utica University librarian, who provided the full texts of the papers.

#### Author contributions

MH: designed the research; FB and DB: performed the eligibility screening and data extraction; MH: resolved conflicts over screening and study selection; FB and DB: wrote the initial manuscript; ND, MS, HP, AH, SD, FK, CA, RM, AE, and MH: critically revised the manuscript; MH: was responsible for study oversight and approval of the final content; and all authors: read and approved the final manuscript.

#### Funding

Open access funding provided by the National Institutes of Health

#### Data availability

No datasets were generated or analysed during the current study.

#### Declarations

**Ethical approval and consent to participate** Not applicable.

#### **Consent for publication**

Not applicable.

#### **Clinical trial number**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

#### Author details

<sup>1</sup>Nutrition and Metabolic Diseases Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>2</sup>Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>3</sup>Department of Biology, School of Arts and Sciences, Utica University, Utica, NY, USA

<sup>4</sup>Physical Medicine and Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>5</sup>Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France

<sup>6</sup>Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran <sup>7</sup>Departments of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran <sup>8</sup>Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

<sup>9</sup>Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran <sup>10</sup>Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA

<sup>11</sup>Epidemiology and Community Health Branch, Division of Intramural Research, Blood Institute, National Heart, National Institutes of Health, Lung, Bethesda, MD, USA

#### Received: 21 May 2024 / Accepted: 21 November 2024 Published online: 28 November 2024

#### References

- Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver diseases. Hepatology (Baltimore MD). 2018;67(1):328–57.
- Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.
- Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterology: WJG. 2011;17(29):3377.
- Kant AK. Dietary patterns: biomarkers and chronic disease risk. Appl Physiol Nutr Metab. 2010;35(2):199–206.
- Watzinger C, Nonnenmacher T, Grafetstätter M, Sowah SA, Ulrich CM, Kauczor H-U, et al. Dietary factors in relation to liver fat content: a cross-sectional study. Nutrients. 2020;12(3):825.
- Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Gastroenterol Hepatol. 2021;36(6):1470–8.
- Zheng J, Zhao L, Dong J, Chen H, Li D, Zhang X, et al. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression: a systematic review. Clin Nutr. 2022;41(10):2295–307.
- Angelidi AM, Papadaki A, Nolen-Doerr E, Boutari C, Mantzoros CS. The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. Metabolism. 2022;129:155136.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
- 10. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014;14:45.
- 11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
- Kaliora AC, Gioxari A, Kalafati IP, Diolintzi A, Kokkinos A, Dedoussis GV. The effectiveness of Mediterranean diet in nonalcoholic fatty liver disease clinical course: an intervention study. J Med Food. 2019;22(7):729–40.
- Trovato FM, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr. 2015;34(1):86–8.
- Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver Int. 2016;36(4):563–71.
- Adriano LS, Sampaio HA, Arruda SP, Portela CL, de Melo MLP, Carioca AA, et al. Healthy dietary pattern is inversely associated with non-alcoholic fatty liver disease in elderly. Br J Nutr. 2016;115(12):2189–95.
- Alferink LJ, Erler NS, de Knegt RJ, Janssen HL, Metselaar HJ, Darwish Murad S, et al. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol. 2020;35(11):1069–85.
- 17. Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C, et al. Adherence to Mediterranean Diet and non-alcoholic fatty liver disease: effect on insulin resistance. Am J Gastroenterol. 2017;112(12):1832–9.
- Chan R, Wong VW, Chu WC, Wong GL, Li LS, Leung J, et al. Diet-Quality scores and Prevalence of nonalcoholic fatty liver disease: a Population Study using Proton-magnetic resonance spectroscopy. PLoS ONE. 2015;10(9):e0139310.
- Choi SH, Oh DJ, Kwon KH, Lee JK, Koh M-S, Lee JH, et al. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): a crosssectional study between buddhist priests and the general population. Turk J Gastroenterol. 2015;26(4):336–43.
- Chung GE, Youn J, Kim YS, Lee JE, Yang SY, Lim JH, et al. Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults. Nutrition. 2019;62:32–8.
- 21. Dehghanseresht N, Jafarirad S, Alavinejad SP, Mansoori A. Association of the dietary patterns with the risk of non-alcoholic fatty liver disease among Iranian population: a case-control study. Nutr J. 2020;19(1):1–9.
- Fakhoury-Sayegh N, Younes H, Heraoui G, Sayegh R. Nutritional Profile and Dietary patterns of Lebanese non-alcoholic fatty liver Disease patients: a case-control study. Nutrients. 2017;9(11).
- Giraldi L, Miele L, Aleksovska K, Manca F, Leoncini E, Biolato M, et al. Mediterranean diet and the prevention of non-alcoholic fatty liver disease: results from a case-control study. Eur Rev Med Pharmacol Sci. 2020;24:7391–8.

- 24. Hashemi Kani A, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Dietary quality indices and biochemical parameters among patients with non alcoholic fatty liver Disease (NAFLD). Hepat Mon. 2013;13(7):e10943.
- Hekmatdoost A, Shamsipour A, Meibodi M, Gheibizadeh N, Eslamparast T, Poustchi H. Adherence to the Dietary approaches to stop hypertension (DASH) and risk of nonalcoholic fatty liver disease. Int J Food Sci Nutr. 2016;67(8):1024–9.
- Jia Q, Xia Y, Zhang Q, Wu H, Du H, Liu L, et al. Dietary patterns are associated with prevalence of fatty liver disease in adults. Eur J Clin Nutr. 2015;69(8):914–21.
- Kalafati IP, Borsa D, Dimitriou M, Revenas K, Kokkinos A, Dedoussis GV. Dietary patterns and non-alcoholic fatty liver disease in a Greek case-control study. Nutrition. 2019;61:105–10.
- 28. Khalatbari-Soltani S, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, et al. The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Med. 2019;17(1):1–14.
- Khalatbari-Soltani S, Marques-Vidal P, Imamura F, Forouhi NG. Prospective association between adherence to the Mediterranean diet and hepatic steatosis: the Swiss CoLaus cohort study. BMJ open. 2020;10(12):e040959.
- Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33(4):678–83.
- Kouvari M, Boutari C, Chrysohoou C, Fragkopoulou E, Antonopoulou S, Tousoulis D, et al. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study. Clin Nutr. 2021;40(5):3314–24.
- Ma J, Hennein R, Liu C, Long MT, Hoffmann U, Jacques PF, et al. Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease. Gastroenterology. 2018;155(1):107–17.
- Park S-Y, Noureddin M, Boushey C, Wilkens LR, Setiawan VW. Diet quality association with nonalcoholic fatty liver disease by cirrhosis status: the multiethnic cohort. Curr Developments Nutr. 2020;4(3):nzaa024.
- Salehi-Sahlabadi A, Sadat S, Beigrezaei S, Pourmasomi M, Feizi A, Ghiasvand R, et al. Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterol. 2021;21(1):1–12.
- Shim P, Choi D, Park Y. Association of blood fatty acid composition and Dietary Pattern with the risk of non-alcoholic fatty liver disease in patients who underwent Cholecystectomy. Ann Nutr Metab. 2017;70(4):303–11.
- Tutunchi H, Saghafi-Asl M, Asghari-Jafarabadi M, Ostadrahimi A. Association between dietary patterns and non-alcoholic fatty liver disease: results from a case-control study. Archives Iran Med (AIM). 2021;24(1).
- Xia Y, Zhang Q, Liu L, Meng G, Wu H, Bao X, et al. Intermediary effect of inflammation on the association between dietary patterns and non-alcoholic fatty liver disease. Nutrition. 2020;71:110562.
- Xiao M-L, Lin J-S, Li Y-H, Liu M, Deng Y-Y, Wang C-Y, et al. Adherence to the Dietary approaches to stop hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults. Public Health Nutr. 2020;23(4):674–82.
- Yang CQ, Shu L, Wang S, Wang JJ, Zhou Y, Xuan YJ, et al. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in Chinese adults. Nutrients. 2015;7(6):4778–91.
- Ghaemi A, Hosseini N, Osati S, Naghizadeh MM, Dehghan A, Ehrampoush E, et al. Waist circumference is a mediator of dietary pattern in non-alcoholic fatty liver disease. Sci Rep. 2018;8(1):4788.
- Abbate M, Mascaró CM, Montemayor S, Barbería-Latasa M, Casares M, Gómez C et al. Energy Expenditure Improved Risk factors Associated with renal function loss in NAFLD and MetS patients. Nutrients. 2021;13(2).
- Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E et al. Effect of Mediterranean Diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study. Nutrients. 2017;9(8).
- 43. Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519–27.
- Biolato M, Manca F, Marrone G, Cefalo C, Racco S, Miggiano GA, et al. Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(4):509–20.
- 45. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Shortterm weight loss and hepatic triglyceride reduction: evidence of a

metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011;93(5):1048–52.

- 46. Franco I, Bianco A, Mirizzi A, Campanella A, Bonfiglio C, Sorino P et al. Physical activity and low Glycemic Index Mediterranean Diet: Main and Modification effects on NAFLD score. Results from a Randomized Clinical Trial. Nutrients. 2020;13(1).
- Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379–88.
- Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120(2):164–75.
- 49. Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, et al. The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial. Nutrients. 2019;11(10):2543.
- Meir AY, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021;70(11):2085–95.
- Misciagna G, Del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, et al. Effect of a low Glycemic Index Mediterranean Diet on non-alcoholic fatty liver disease. A Randomized Controlled Clinici Trial. J Nutr Health Aging. 2017;21(4):404–12.
- Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food. 2011;14(7–8):677–80.
- Pintó X, Fanlo-Maresma M, Corbella E, Corbella X, Mitjavila MT, Moreno JJ, et al. A Mediterranean diet rich in extra-virgin olive oil is associated with a reduced prevalence of nonalcoholic fatty liver disease in older individuals at high cardiovascular risk. J Nutr. 2019;149(11):1920–9.
- Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, et al. Ad Libitum Mediterranean and Low-Fat diets both significantly reduce hepatic steatosis: a Randomized Controlled Trial. Hepatology. 2018;68(5):1741–54.
- Ristic-Medic D, Kovacic M, Takic M, Arsic A, Petrovic S, Paunovic M et al. Calorie-restricted Mediterranean and Low-Fat diets affect fatty acid status in individuals with nonalcoholic fatty liver disease. Nutrients. 2020;13(1).
- Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43.
- Maskarinec G, Lim U, Jacobs S, Monroe KR, Ernst T, Buchthal SD, et al. Diet Quality in Midadulthood predicts visceral adiposity and liver fatness in older ages: the multiethnic cohort study. Obes (Silver Spring). 2017;25(8):1442–50.
- Chacon V, Cara KC, Chung M, Wallace TC. Defining low-carb in the scientific literature: a scoping review of clinical studies. Crit Rev Food Sci Nutr. 2023:1–10.
- Menotti A, Puddu P. How the Seven Countries Study contributed to the definition and development of the Mediterranean diet concept: a 50-year journey. Nutr Metabolism Cardiovasc Dis. 2015;25(3):245–52.
- Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348(26):2599–608.
- Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI et al. The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial. Nutrients. 2019;11(10).
- Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011;57(11):1299–313.
- 63. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012;32(5):701–11.

- Diaz-Vegas A, Sanchez-Aguilera P, Krycer JR, Morales PE, Monsalves-Alvarez M, Cifuentes M, et al. Is mitochondrial dysfunction a common root of noncommunicable chronic diseases? Endocr Rev. 2020;41(3):bnaa005.
- Lin P-H, Aickin M, Champagne C, Craddick S, Sacks FM, McCarron P, et al. Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial. J Am Diet Assoc. 2003;103(4):488–96.
- Schutte S, Esser D, Hoevenaars FP, Hooiveld GJ, Priebe MG, Vonk RJ, et al. A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. Am J Clin Nutr. 2018;108(6):1264–74.
- 67. Zhang S, Fu J, Zhang Q, Liu L, Meng G, Yao Z, et al. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int. 2019;39(9):1732–41.
- Salomone F, Godos J, Zelber-Sagi S. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver Int. 2016;36(1):5–20.
- English LK, Ard JD, Bailey RL, Bates M, Bazzano LA, Boushey CJ, et al. Evaluation of dietary patterns and all-cause mortality: a systematic review. JAMA Netw open. 2021;4(8):e2122277–e.
- Hashemian M, Farvid MS, Poustchi H, Murphy G, Etemadi A, Hekmatdoost A, et al. The application of six dietary scores to a Middle Eastern population: a comparative analysis of mortality in a prospective study. Eur J Epidemiol. 2019;34(4):371–82.
- Wang Q, Hashemian M, Sepanlou SG, Sharafkhah M, Poustchi H, Khoshnia M, et al. Dietary quality using four dietary indices and lung cancer risk: the Golestan Cohort Study (GCS). Cancer Causes Control. 2021;32(5):493–503.
- Reedy J, Krebs-Smith SM, Miller PE, Liese AD, Kahle LL, Park Y, et al. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr. 2014;144(6):881–9.
- 73. Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 2018;41(8):1732–9.
- Hashemian M, Merat S, Poustchi H, Jafari E, Radmard A-R, Kamangar F, et al. Red meat consumption and risk of nonalcoholic fatty liver disease in a population with low meat consumption: the Golestan Cohort Study. Am J Gastroenterol. 2021;116(8):1667–75.
- van Eekelen E, Geelen A, Alssema M, Lamb HJ, de Roos A, Rosendaal FR, et al. Sweet snacks are positively and fruits and vegetables are negatively Associated with Visceral or Liver Fat Content in Middle-aged men and women. J Nutr. 2019;149(2):304–13.
- Dorosti M, Heidarloo AJ, Bakhshimoghaddam F, Alizadeh M. Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial. Br J Nutr. 2020;123(3):328–36.
- Bahrami A, Teymoori F, Eslamparast T, Sohrab G, Hejazi E, Poustchi H, et al. Legume intake and risk of nonalcoholic fatty liver disease. Indian J Gastroenterol. 2019;38(1):55–60.
- Keshavarz Z, Rahimlou M, Farjam M, Homayounfar R, Khodadost M, Abdollahi A, et al. Non-alcoholic fatty liver disease and dairy products consumption: results from FASA Persian cohort study. Front Nutr. 2022;9:962834.
- 79. Jung S, Bae H, Song W-S, Jang C. Dietary Fructose and Fructose-Induced pathologies. Annu Rev Nutr. 2022;42:45–66.
- Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014;6(12):5679–703.
- Seid H, Rosenbaum M. Low carbohydrate and low-fat diets: what we don't know and why we should know it. Nutrients. 2019;11(11):2749.
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.